Skip to main content
. Author manuscript; available in PMC: 2015 Jan 29.
Published in final edited form as: Exp Eye Res. 2012 May;98:88–96. doi: 10.1016/j.exer.2012.03.017

Table 1.

Normal control and retinal degenerative subjects identifying data.

ID
Index
Age
(yr)
Gender Clinical Diagnosis Age of RD
Onset (yr)
Mutation Visual Acuity Family History ERG-Jet
Threshold (mA)
NC 1 47.5 F n/a n/a n/a n/a n/a 0.55
NC 2 27.0 M n/a n/a n/a n/a n/a 0.80
NC 3 24.0 M n/a n/a n/a n/a n/a 0.60
NC 4 41.8 F n/a n/a n/a n/a n/a 1.00
NC 5 31.4 M n/a n/a n/a n/a n/a 0.65
RD 1 42.1 F Leber’s congenital amaurosis (LCA) 14 CRXa OU light perception Relative with AMD & LCA 4.5
RD 2 32.0 M Bull’s eye cone-rod dystrophy Stargardt (Group 3) 4 ABCA4 G1725 OU finger counting up to 1 ft No family history 1.6
RD 3 56.7 M Retinitis pigmentosa 14 Not foundb OU light perception No family history 2.5
RD 4 52.2 M Retinitis pigmentosa 20 Not foundb OU light perception No family history 5.8
RD 5 35.7 M Retinitis pigmentosa 4 Not foundb OU light perception No family history 1.0

AMD: age-related macular degeneration; F: female; LCA: Leber’s congenital amaurosis; M: male; NC: normal control; RD: retinal degenerative subject; OU: both eyes.

a

Novel, non-published CRX mutation.

b

Non-published, de novo mutation basedongene screening for CERKL, CNGB1, MERTK, PDE6B, PNR, RDH12, RGR, RLBP1, SAG, TULP1, CRB, RPE65, USH3A, LRAT, and PROM1 (ARRPgenetest, Asper Ophthalmics, Tartu, Estonia).